Zhong Xiaojing, Fan Jiajia
Xiaojing Zhong, Department of Endocrinology, Huzhou Central Hospital, 1558 Sanhuan North Road, Huzhou, Zhejiang Province 313003, P.R. China.
Jiajia Fan, Department of General Medicine, Huzhou Central Hospital, 1558 Sanhuan North Road, Huzhou, Zhejiang Province 313003, P.R. China.
Pak J Med Sci. 2024 Aug;40(7):1410-1414. doi: 10.12669/pjms.40.7.9214.
To explore the effect of Atorvastatin combined with Irbesartan in the treatment of early diabetic nephropathy (DN).
Clinical data from 153 patients with early DN, admitted to Huzhou Central Hospital from January 2020 to December 2022, was retrospectively selected. Patients were divided into two groups based on the treatment they received: patients received Irbesartan treatment alone were assigned to Irbesartan group (n=74); patients received Irbesartan combined with Atorvastatin were assigned to combined group (n=79). Levels of renal function indicators, renal fibrosis indicators, micro inflammatory status indicators, and incidence of adverse reactions were compared between the two groups before and after the treatment.
After the treatment, indicators of renal function, renal fibrosis and micro-inflammation in both groups significantly decreased compared to pretreatment levels (<0.05), and were significantly lower in the combined group compared to Irbesartan group (<0.05). There was no significant difference in the incidence of adverse reactions between the groups (>0.05).
Compared with Irbesartan alone, Atorvastatin combined with Irbesartan is more effective in the treatment of early DN. Combined treatment regimen is able to effectively reduces the micro-inflammatory state, improve renal function and fibrosis, and is not associated with the increased risk of adverse reactions.
探讨阿托伐他汀联合厄贝沙坦治疗早期糖尿病肾病（DN）的效果。
回顾性选取2020年1月至2022年12月在湖州市中心医院收治的153例早期DN患者的临床资料。根据患者接受的治疗方法将其分为两组：单纯接受厄贝沙坦治疗的患者被分配至厄贝沙坦组（n = 74）；接受厄贝沙坦联合阿托伐他汀治疗的患者被分配至联合组（n = 79）。比较两组治疗前后的肾功能指标、肾纤维化指标、微炎症状态指标及不良反应发生率。
治疗后，两组的肾功能、肾纤维化和微炎症指标均较治疗前显著降低（<0.05），且联合组显著低于厄贝沙坦组（<0.05）。两组间不良反应发生率无显著差异（>0.05）。
与单纯使用厄贝沙坦相比，阿托伐他汀联合厄贝沙坦治疗早期DN更有效。联合治疗方案能够有效降低微炎症状态，改善肾功能和纤维化，且不增加不良反应风险。
